Atlantic Therapeutics Group Ltd

Atlantic Therapeutics Group Ltd, based in Ireland, specializes in innovative solutions for urinary incontinence, offering non-invasive treatments that empower women to regain control over their pelvic health. Founded in 2013 in Galway, Ireland, Atlantic Therapeutics Group Ltd develops advanced medical devices targeting urinary incontinence. The company has engaged in 8 deals, with its most recent funding round being a Series B that raised EUR 15. 220 mn on September 6, 2023.

The company is led by CEO Susan Trent. INNOVO is Atlantic Therapeutics' primary offering, a non-invasive device for women experiencing stress urinary incontinence. The FDA-cleared INNOVO kit employs multipath technology to deliver 180 targeted Kegel exercises in a 30-minute session, effectively strengthening pelvic floor muscles. Targeted mainly at adult women, including new mothers and menopausal individuals, INNOVO aims to restore confidence and support an active lifestyle free from bladder leakage issues.

The products are marketed in multiple international markets, including the United States, Canada, and several European nations. The revenue of INNOVO primarily comes from direct-to-consumer sales of its urinary incontinence treatment kit and related items, such as supplemental shorts and sprays. The INNOVO Urinary Incontinence Kit is priced at USD 349, with additional products like the INNOVO Spray available for USD 25. 95.

This direct sales model facilitates a seamless purchasing experience for consumers, positioning the company effectively within the women's health product market. Following its acquisition in September 2023 by Caldera Medical, Inc. , Atlantic Therapeutics Group Ltd aims to leverage the funding to enhance the scalability of its INNOVO products and expand its offerings in the women's health sector globally. The acquisition is expected to facilitate entry into new geographic markets and the development of upcoming products, although specific release dates have yet to be disclosed.